Molecular Screening and Therapeutics (MoST) study

The MoST study uses the power of genomic technology to characterise molecular changes in a patient's cancer that may help to identify a targeted therapy.

MoST has a number of different screening populations

Our program — covers all different types of cancers:

Leukaemia and lymphoma subprogram (MoST-LLy) – Open for screening – for more information see MoST-LLY at QIMR Berghofer

  • for patients with advanced blood cancers without an established therapeutic option.

Pan cancer subprogram (MoST and AYA-MoST) – Closed to new recruitment – see CaSP to refer patients for molecular screening

  • for patients, including Adolescents and Young Adults (AYA), with pathologically-confirmed advanced or metastatic solid cancers of any histological type, either during or after their last line of effective therapy.

Lung cancer subprogram (ASPiRATION) –Closed to new recruitment – see CaSP to refer patients for molecular screening

  • for adults with newly diagnosed, pathologically-confirmed metastatic non-squamous non-small cell lung cancer (NSCLC), with sufficient and accessible tissue for molecular screening.

 

MoST clinical trials

We are using the power of genomic technology to characterise molecular changes in a patient’s cancer that may help to identify a targeted therapy.

ASPiRATION

An observational cohort study to assess the clinical impact of comprehensive genomic profiling in metastatic lung cancer patients.

MoST-LLy

A clinical trial research program offering Australians with blood cancer genomic screening and potential access to precision medicines.

MoST has two stages

Stage 1
We use genomic profiling to analyse the molecular characteristics of a patient’s tumour, we gather as much genetic and clinical information as we can to help us identify specific characteristics about the tumour.

A team of experts review the molecular profile of the tumour with other clinical and patient information. A report is provided to the referring clinician.

Stage 2
Patients identified as possessing any of a range of molecular characteristics (identified during Stage 1) may be eligible to access treatment in a MoST therapeutic study (a clinical trial) or other targeted therapy.

Who can participate in MoST?

Pan cancer subprogram: Patients aged 16 years and older with an advanced and/or metastatic solid or blood cancer with limited treatment options, and who are willing and fit enough to participate in a clinical trial, are eligible.

Lung cancer subprogram: Patients aged 18 years and older with newly diagnosed metastatic non-squamous non-small cell lung cancer (NSCLC), who have not had any previous treatment for the lung cancer and who are willing and fit enough to participate in a clinical trial, are eligible.

Your treating oncologist will assess your eligibility, complete the MoST referral forms, and provide all relevant information.

What does participation involve?

For patients

  • Discussing the study with the MoST team (either by telephone or face-to-face)
  • Consenting to the access of samples held by pathology centres
  • Consenting to the access of their medical records
  • Donating a blood sample
  • Completing questionnaires
  • Providing optional consent for access to Medicare/PBS data

Interested in knowing more?

Get in touch